Interestingly, gastric cancer in vivo models with high ATM expression exhibited more resistance to irinotecan monotherapy but achieved a more marked improvement in tumour growth inhibition when combined with PARPi therapy [139]. The gene discussed is ATM; the disease is neoplasm.